ArticleThe Lancet. Infectious diseases2019

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.

Kayvon Modjarrad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.